Harshika Sarbajna | Global Head, Anti-infectives
Sandoz International GmbH

Harshika Sarbajna, Global Head, Anti-infectives, Sandoz International GmbH

Harshika Sarbajna recently assumed the role of Global Head of Anti-Infectives, Oral, for Sandoz (a Novartis Division) and is responsible for ensuring sustainable access to and promoting proper use of anti-infectives.
In this role, she is also spearheading the Sandoz/Novartis wide AMR Stewardship program, bringing together stakeholders both inside and outside the organization. She is committed to driving practical, scalable solutions that deliver meaningful impact in combating AMR.
She previously served as the Global Head of Strategy and Operations for the Biopharmaceuticals business unit within Sandoz. During Harshika’s tenure in Biopharmaceuticals, she successfully navigated a dynamic marketplace, working across functions to develop and implement a strategy that saw three positive CHMP positive opinions and two EC approvals in the last 12 months.
Prior to Sandoz, Harshika served as Head of business strategy for the biosimilars business at Dr. Reddy’s Lab, and drove growth across the portfolio in key markets including the US, Asia, Latin America and Russia. Before joining Dr. Reddy’s, she led various executive-level advisory engagements on business and growth strategy for large Corporates. Harshika began her career at Infosys, working with retail businesses across Europe and the US on their customer acquisition and retention strategy.


World Anti-Microbial Resistance Congress USA 2018 - Day 1 @ 17:30

Keynote CEO Panel: How to do business in a challenging environment - Current landscape for biotechs looking to commercialize or commercializing antimicrobials

  • How do you turn the current antibiotic development and commercialization model into one that is attractive to big pharma
  • Partnering and business development opportunities for smaller antibiotic biotechs – overcoming low stock prices
  • How can developing companies survive in this space and get continuous investments? Is the emergence of smaller companies the way to commercial viability and efficient distribution of resources
  • What is the investment landscape going to look like for up and coming companies
  • How to launch a product and demonstrate commercial success

World Anti-Microbial Resistance Congress USA 2018 - Day 2 @ 14:00

Roundtable 6: Industry Collaboration – Translating commitments across all fronts into meaningful impact in the fight against AMR

last published: 12/Oct/18 20:55 GMT

back to speakers